SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.

Publication date: Jul 17, 2023

Despite advances, few therapeutics have shown efficacy in severe coronavirus disease 2019 (COVID-19). In a different context, virus-specific T cells have proven safe and effective. We conducted a randomized (2:1), open-label, phase 1/2 trial to evaluate the safety and efficacy of off-the-shelf, partially human leukocyte antigen (HLA)-matched, convalescent donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells (CoV-2-STs) in combination with standard of care (SoC) in patients with severe COVID-19 compared to SoC during Delta variant predominance. After a dose-escalated phase 1 safety study, 90 participants were randomized to receive CoV-2-ST+SoC (n = 60) or SoC only (n = 30). The co-primary objectives of the study were the composite of time to recovery and 30-d recovery rate and the in vivo expansion of CoV-2-STs in patients receiving CoV-2-ST+SoC over SoC. The key secondary objective was survival on day 60. CoV-2-ST+SoC treatment was safe and well tolerated. The study met the primary composite endpoint (CoV-2-ST+SoC versus SoC: recovery rate 65% versus 38%, P = 0. 017; median recovery time 11 d versus not reached, P = 0. 052, respectively; rate ratio for recovery 1. 71 (95% confidence interval 1. 03-2. 83, P = 0. 036)) and the co-primary objective of significant CoV-2-ST expansion compared to SοC (CoV-2-ST+SoC versus SoC, P = 0. 047). Overall, in hospitalized patients with severe COVID-19, adoptive immunotherapy with CoV-2-STs was feasible and safe. Larger trials are needed to strengthen the preliminary evidence of clinical benefit in severe COVID-19.

Concepts Keywords
Coronavirus Cov
Immunotherapy Covid
Therapy P=0
Tolerated Phase


Type Source Name
disease IDO cell
disease MESH COVID-19
disease VO effective
disease VO Severe acute respiratory syndrome coronavirus 2
drug DRUGBANK Sodium Tetradecyl Sulfate
disease VO dose
disease VO time
drug DRUGBANK Methionine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *